Company intelligence / Profile preview
Allogene Therapeutics
South San Francisco, California, United Statesallogene.com ↗
- Ownership
- Public · ALLO
- Employees
- ~500
- Development stage
- Phase 2
01
Overview
Allogene's lead product cemacabtagene ansegedleucel (cema-cel) showed promising results in Phase 1 ALPHA/ALPHA2 trials for relapsed/refractory LBCL with overall response rates of 58% and complete response rates of 42% across the study, and 67% and 58% with the pivotal study regimen, respectively. Among patients who achieved complete response, median duration of response was 23.1 months and median overall survival was not reached. The company is now conducting the pivotal Phase 2 ALPHA3 trial for first-line consolidation in LBCL. ALLO-316 for renal cell carcinoma has shown meaningful response rates in Phase 1 trials, and ALLO-329 for autoimmune diseases has received FDA IND clearance.[5][9]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic CAR T cell therapy (AlloCAR T™)
- Industry
- Biotech
02
Drug pipeline
27 assets26 more assets in the full pipeline.
03
Partnerships
Arbor BiotechnologiesForesight Diagnostics
04
Financials
- Market cap
- $376.6M
- Total revenue
- $0
- Enterprise value
- $114.3M
Beyond the preview
Go deeper on Allogene Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogene Therapeutics.